## Does exa-cel CRISPR Therapy Work in Children Under 12?

**8 out of 8 children with sickle cell disease remained free from severe vaso-occlusive crises for at least 12 months. All 8 evaluable children with transfusion-dependent beta thalassemia achieved transfusion independence for at least 12 months.** Those are the headline numbers from a phase 3 study of exagamglogene autotemcel (exa-cel) in children ages 5–11, published June 29, 2026 in *The New England Journal of Medicine* and announced by HCA Healthcare.

The study, led by Dr. Haydar Frangoul — medical director of HCA Healthcare's Sarah Cannon Transplant and Cellular Therapy Program at TriStar Centennial Children's Hospital — enrolled 26 children across two phase 3 trials: 15 with transfusion-dependent beta thalassemia and 11 with sickle cell disease. The data represent the first published evaluation of exa-cel specifically in the 5–11 age cohort. The trial was sponsored by Vertex Pharmaceuticals.

This matters because exa-cel, a [CRISPR-Cas9](https://synbiointel.com/glossary/crispr-cas9)-based autologous [cell therapy](https://synbiointel.com/glossary/cell-therapy), currently holds FDA approval only for patients ages 12 and older. Demonstrating efficacy and tolerability in younger children opens a regulatory pathway to earlier intervention — potentially before years of cumulative organ damage, pain crises, and transfusion burden accumulate.

---

## What the NEJM Data Actually Show

The 26-child cohort was split across two pre-existing phase 3 studies. Among the subset followed long enough to reach primary endpoints:

- **All 8 children with sickle cell disease** were free from severe vaso-occlusive crises for at least 12 months post-treatment.
- **All 8 children with beta thalassemia** achieved transfusion independence for at least 12 months.

The mechanism: exa-cel edits the patient's own blood-forming stem cells *ex vivo* to upregulate fetal hemoglobin production. Fetal hemoglobin does not polymerize like the mutant adult hemoglobin driving sickle cell pathology, and its expression can substitute for the deficient adult hemoglobin in beta thalassemia. Patients undergo myeloablative conditioning chemotherapy before the modified cells are reinfused — a significant procedural burden that the source text acknowledges but does not quantify in terms of adverse events in this cohort.

**What the source does not report:** off-target editing rates, long-term engraftment data beyond 12 months, or a comparison arm. The 8/8 response figures are striking, but they apply only to the evaluable subset — not all 26 enrolled children had been followed long enough to hit primary endpoints at the time of publication. Investors and clinicians should weight that caveat appropriately.

---

## The Investigator Profile and What It Signals

Dr. Frangoul is not new to this space. According to HCA Healthcare, he was previously a principal investigator in the first U.S. clinical trial to use gene editing for sickle cell disease — work that contributed to the development of the first FDA-approved CRISPR-based therapy in the U.S. for patients 12 and older. In 2026 alone, he has authored five gene-editing studies published in *NEJM*, which is an unusual concentration of output from a single clinical site and suggests that TriStar Centennial / Sarah Cannon has become one of the more productive nodes in the CRISPR hemoglobinopathy trial network.

Sarah Cannon Transplant and Cellular Therapy Network reports performing more than 1,600 blood and marrow transplants and cellular therapies annually across its network — a throughput figure that matters for any analysis of real-world exa-cel deployment capacity.

---

## Pediatric Age Extension: The Regulatory and Commercial Logic

The FDA currently approves exa-cel for patients ages 12 and older. The 5–11 cohort data, if they hold and are corroborated in a larger follow-up, would form the clinical basis for a supplemental BLA or equivalent submission to extend the label. The CDC estimates approximately 100,000 people in the United States live with sickle cell disease; the condition is the most common inherited blood disorder in the U.S. Severe beta thalassemia affects a smaller but still significant domestic population.

Treating at age 5–11 rather than waiting until 12+ has a plausible biological rationale: sickle cell disease causes progressive splenic and renal injury, stroke risk, and neurocognitive effects that begin accumulating in early childhood. A one-time intervention that durably eliminates vaso-occlusive crises or transfusion dependence before those injuries compound would represent a fundamentally different disease course than treating adolescents who have already sustained years of organ stress.

From a market access standpoint, a pediatric label extension also matters for payer negotiations. Demonstrating efficacy in younger patients — and potentially modeling lifetime cost offsets against avoided hospitalizations, transfusions, chelation therapy, and organ damage — strengthens the pharmacoeconomic case for a therapy that carries a substantial upfront cost.

---

## HCA's Infrastructure Play

HCA Healthcare is not simply a passive clinical trial site here. The announcement notes that TriStar Centennial Children's Hospital in Nashville and Methodist Children's Hospital in San Antonio currently offer FDA-approved gene-editing therapies for eligible patients, with Medical City Children's Hospital in Dallas in preparation to expand services. That is a deliberate network build-out, positioning HCA as one of the few hospital systems with the procedural infrastructure — myeloablative conditioning suites, stem cell processing, long-term follow-up protocols — to deliver autologous CRISPR therapies at scale.

The Sarah Cannon Research Institute's role as a co-investigator also reinforces HCA's stated strategy of using its scale (189 hospitals, more than 2,600 ambulatory sites) to generate clinical evidence, not just administer approved therapies.

---

## Industry Trajectory

This data set advances the broader CRISPR therapeutics field in a specific and measurable way: it begins the age de-escalation process for the first approved CRISPR medicine. The field has watched exa-cel's approval for 12+ closely, but the real clinical and commercial prize has always been earlier intervention. A successful pediatric label extension would also provide a template that other CRISPR and [base editing](https://synbiointel.com/glossary/base-editing) programs targeting hemoglobinopathies — several of which are in earlier clinical stages — can reference for trial design and endpoint selection.

The skeptical read: with only 8 evaluable patients per arm at the time of publication, these are promising but statistically thin data. The 26-child cohort needs longer follow-up, and the full dataset needs independent analysis for durability, off-target burden, and conditioning-related toxicity before the 8/8 figures are treated as definitive. *NEJM* publication is meaningful peer review, but it is not the same as a complete regulatory package.

---

## Key Takeaways

- **All 8 evaluable sickle cell children** (ages 5–11) remained free from severe vaso-occlusive crises for at least 12 months after exa-cel treatment.
- **All 8 evaluable beta thalassemia children** achieved transfusion independence for at least 12 months.
- The total enrolled cohort was **26 children**; not all had reached primary endpoints at time of publication.
- exa-cel is currently **FDA-approved for ages 12 and older**; this data supports a potential pediatric label extension.
- The trial was **sponsored by Vertex Pharmaceuticals** and conducted through HCA Healthcare's Sarah Cannon network.
- Dr. Frangoul has published **five gene-editing studies in NEJM in 2026 alone**, signaling TriStar Centennial as a high-output clinical site.
- HCA is actively **expanding gene-editing therapy access** across children's hospitals in Nashville, San Antonio, and (in preparation) Dallas.
- The mechanism — fetal hemoglobin re-activation via CRISPR editing of autologous stem cells — requires myeloablative conditioning, a nontrivial procedural burden not yet quantified for this cohort.

---

## Frequently Asked Questions

**What is exa-cel and how does it work?**
Exagamglogene autotemcel (exa-cel) is a CRISPR-Cas9-based autologous cell therapy developed by Vertex Pharmaceuticals. It works by editing a patient's own blood-forming stem cells *ex vivo* to increase production of fetal hemoglobin, which can compensate for dysfunctional adult hemoglobin in both sickle cell disease and beta thalassemia.

**Is exa-cel approved for children under 12?**
As of the time of this publication, exa-cel's FDA approval covers patients ages 12 and older. The NEJM study published June 29, 2026 presents phase 3 data for children ages 5–11, which would form the basis for a potential supplemental regulatory submission to extend the label to younger patients.

**How many children were in the study?**
26 children ages 5–11 were enrolled: 15 with transfusion-dependent beta thalassemia and 11 with sickle cell disease. At the time of publication, 8 in each group had been followed long enough to evaluate primary endpoints, and all 8 in each arm met those endpoints.

**Which hospitals are currently offering exa-cel to eligible patients?**
According to HCA Healthcare, TriStar Centennial Children's Hospital in Nashville and Methodist Children's Hospital in San Antonio currently offer FDA-approved gene-editing therapies for eligible patients. Medical City Children's Hospital in Dallas is preparing to expand services.

**What are the limitations of this data?**
The evaluable subsets are small (8 per arm), follow-up is limited to the 12-month primary endpoint window, and the source publication does not report off-target editing rates or conditioning-related adverse event profiles for this cohort. Longer follow-up and larger cohorts will be required before the pediatric label extension case is complete.